Detection of immunity in sheep following anti-rabies vaccination.

IF 2.1 Q4 IMMUNOLOGY
Hasanthi Rathnadiwakara, Mangala Gunatilake, Florence Cliquet, Marine Wasniewski, Mayuri Thammitiyagodage, Ramani Karunakaran, Jean-Christophe Thibault, Mohamed Ijas
{"title":"Detection of immunity in sheep following anti-rabies vaccination.","authors":"Hasanthi Rathnadiwakara,&nbsp;Mangala Gunatilake,&nbsp;Florence Cliquet,&nbsp;Marine Wasniewski,&nbsp;Mayuri Thammitiyagodage,&nbsp;Ramani Karunakaran,&nbsp;Jean-Christophe Thibault,&nbsp;Mohamed Ijas","doi":"10.7774/cevr.2023.12.2.97","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Rabies is a fatal but preventable disease with proper pre-exposure anti-rabies vaccination (ARV). Dogs, as household pets and strays, are the reservoir and vector of the disease, and dog bites have been associated with human rabies cases in Sri Lanka over the past few years. However, other susceptible species having frequent contact with humans may be a source of infection. One such species is sheep and immunity following ARV has never been tested in sheep reared in Sri Lanka.</p><p><strong>Materials and methods: </strong>We have tested serum samples from sheep reared in the Animal Centre, Medical Research Institute of Sri Lanka for the presence of anti-rabies antibodies following ARV. Sheep serum samples were tested with Bio-Pro Rabies enzyme-linked immunosorbent assay (ELISA) antibody kits used for the first time in Sri Lanka and our results were verified by a seroneutralization method on cells (fluorescent antibody virus neutralization, FAVN test) currently recommended by World Organization for Animal Health and World Health Organization.</p><p><strong>Results: </strong>Sheep received annual ARV and maintained high neutralizing antibody titers in their serum. No maternal antibodies were detected in lamb around 6 months of age. Agreement between the ELISA and FAVN test, i.e., coefficient concordance was 83.87%.</p><p><strong>Conclusion: </strong>Annual vaccination in sheep has an effect on maintaining adequate protection against rabies by measurements of anti-rabies antibody response. Lambs need to be vaccinated earlier than 6 months of age to achieve protective levels of neutralizing antibodies in their serum. Introducing this ELISA in Sri Lanka will be a good opportunity to determine the level of anti-rabies antibodies in animal serum samples.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"12 2","pages":"97-106"},"PeriodicalIF":2.1000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/71/d5/cevr-12-97.PMC10193110.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2023.12.2.97","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Rabies is a fatal but preventable disease with proper pre-exposure anti-rabies vaccination (ARV). Dogs, as household pets and strays, are the reservoir and vector of the disease, and dog bites have been associated with human rabies cases in Sri Lanka over the past few years. However, other susceptible species having frequent contact with humans may be a source of infection. One such species is sheep and immunity following ARV has never been tested in sheep reared in Sri Lanka.

Materials and methods: We have tested serum samples from sheep reared in the Animal Centre, Medical Research Institute of Sri Lanka for the presence of anti-rabies antibodies following ARV. Sheep serum samples were tested with Bio-Pro Rabies enzyme-linked immunosorbent assay (ELISA) antibody kits used for the first time in Sri Lanka and our results were verified by a seroneutralization method on cells (fluorescent antibody virus neutralization, FAVN test) currently recommended by World Organization for Animal Health and World Health Organization.

Results: Sheep received annual ARV and maintained high neutralizing antibody titers in their serum. No maternal antibodies were detected in lamb around 6 months of age. Agreement between the ELISA and FAVN test, i.e., coefficient concordance was 83.87%.

Conclusion: Annual vaccination in sheep has an effect on maintaining adequate protection against rabies by measurements of anti-rabies antibody response. Lambs need to be vaccinated earlier than 6 months of age to achieve protective levels of neutralizing antibodies in their serum. Introducing this ELISA in Sri Lanka will be a good opportunity to determine the level of anti-rabies antibodies in animal serum samples.

Abstract Image

Abstract Image

Abstract Image

绵羊抗狂犬病疫苗免疫检测。
目的:狂犬病是一种致命但可通过适当的暴露前抗狂犬病疫苗(ARV)预防的疾病。作为家庭宠物和流浪狗的狗是该病的宿主和媒介,在过去几年中,斯里兰卡发生了与人类狂犬病病例有关的狗咬伤事件。然而,与人类经常接触的其他易感物种可能是感染源。绵羊就是这样一个物种,在斯里兰卡饲养的绵羊中从未测试过抗逆转录病毒病毒后的免疫力。材料和方法:我们对斯里兰卡医学研究所动物中心饲养的羊的血清样本进行了检测,以确定抗逆转录病毒治疗后是否存在抗狂犬病抗体。采用斯里兰卡首次使用的Bio-Pro狂犬病酶联免疫吸附试验(ELISA)抗体试剂盒对绵羊血清样本进行检测,并采用世界动物卫生组织和世界卫生组织目前推荐的细胞血清中和法(荧光抗体病毒中和法,FAVN试验)对结果进行验证。结果:绵羊每年接受ARV治疗,血清中保持较高的中和抗体滴度。在6月龄左右的羔羊中未检测到母源抗体。ELISA与FAVN检测结果的一致性为83.87%。结论:绵羊每年接种狂犬病疫苗可通过检测抗狂犬病抗体反应来维持对狂犬病的充分保护。羔羊需要在6个月之前接种疫苗,以达到其血清中中和抗体的保护水平。在斯里兰卡引进这种酶联免疫吸附试验将是确定动物血清样本中抗狂犬病抗体水平的良好机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信